Upregulation of HMGA2 participates in several mechanisms such as E2F7-mediated repression of pro-apoptotic effects of E2F1, cell cycle delay until the DNA damage is repaired, cancer cell survival, and development of chemoresistance, that confer survival-specific and evasion of immune surveillance (via downregulation of IL6, IL1R1 and upregulation of chemokines such as CXCL13 and CXCL14) advantage to cancer cells. The gene discussed is E2F1; the disease is cancer.